PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer

Zacks10-09

PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474402814?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZcqDt7bCeBMLkGs_KJ1O8A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1","is_english":true,"pubTime":"2024-10-09 00:42","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474402814","market":"us","top_or_hot":-1,"title":"PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer","media":"Zacks","content":"<div>\n<p>PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/prct-stock-rises-fdas-nod-164200364.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-09 00:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/prct-stock-rises-fdas-nod-164200364.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to ...</p>\n\n<a href=\"https://finance.yahoo.com/news/prct-stock-rises-fdas-nod-164200364.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSP","symbol_name":"Inspire Medical Systems","start_time":0,"source_url":"https://finance.yahoo.com/news/prct-stock-rises-fdas-nod-164200364.html","article_id":"2474402814","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZcqDt7bCeBMLkGs_KJ1O8A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/228e67967b066e7a755ae3614be720e1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474402814","pubTimestamp":1728405720,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"PROCEPT BioRobotics Corporation PRCT recently announced that it has received theFDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for patients with prostate cancer.This approval marks a critical step in the company's objective to revolutionize treatment options for patients suffering from prostate cancer. The company also recently received Breakthrough Device Designation to investigate the use of Aquablation therapy for prostate cancer.Following the announcement, shares of the company moved north 4.9% in the after-market session on Monday.PRCT’s innovative solutions, particularly Aquablation therapy, have positioned the company as a major player in the medical robotics space. With this FDA approval, the company is expected to gain traction among investors looking for growth opportunities in the healthcare sector.Meanwhile, PRCT currently","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSP":"Inspire Medical Systems","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","LU0238689110.USD":"贝莱德环球动力股票基金","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BSX":"波士顿科学","BK4082":"医疗保健设备","PRCT":"PROCEPT BioRobotics","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","BK4167":"医疗保健技术","BK4588":"碎股","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","BK4581":"高盛持仓","BK4504":"桥水持仓","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","TMDX":"TransMedics Group Inc.","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC"},"translate_title":"FDA同意启动前列腺癌研究，PRCT股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1,"PRCT":1,"INSP":1,"BSX":0.9},"content_text":"PROCEPT BioRobotics Corporation PRCT recently announced that it has received the FDA’s approval to commence a pivotal Investigational Device Exemption clinical trial comparing Aquablation therapy to radical prostatectomy. The study will evaluate the efficacy of Aquablation therapy for patients with prostate cancer.\nThis approval marks a critical step in the company's objective to revolutionize treatment options for patients suffering from prostate cancer. The company also recently received Breakthrough Device Designation to investigate the use of Aquablation therapy for prostate cancer.\nLikely Trend of PRCT Stock Following the News\nFollowing the announcement, shares of the company moved north 4.9% in the after-market session on Monday.\nPRCT’s innovative solutions, particularly Aquablation therapy, have positioned the company as a major player in the medical robotics space. With this FDA approval, the company is expected to gain traction among investors looking for growth opportunities in the healthcare sector.\nFor the year-to-date period, PRCT shares have lost 41.6% against the industry’s rise of 10.7%. The S&P 500 increased 19.6% in the same time frame.\nMeanwhile, PRCT currently has a market capitalization of $3.77 billion. In the last reported quarter, PRCT delivered an earnings surprise of 3.9%.\nFind the latest earnings estimates and surprises on the Zacks Earnings Calendar.\nImage Source: Zacks Investment Research\nMore on Aquablation Therapy\nAquablation therapy is the first and only ultrasound-guided, robotic-assisted, heat-free waterjet for the treatment of benign prostatic hyperplasia (BPH). The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy.\nThe surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted, and controlled fashion.\nMore on PRCT’s Initial Study\nThe WATER IV PCa trial is a prospective, randomized, multicenter, worldwide clinical study that evaluates the safety and effectiveness of Aquablation therapy in comparison to radical prostatectomy for men with Grade Group 1 to 3 localized prostate cancer. Up to 280 individuals will be enrolled in the trial at up to 50 centers, and they will be followed for 10 years.\nThere is a co-primary endpoint based on morbidity evaluated at the six-month follow-up. Oncologic events and treatment-related damage reduction are the main goals of longer-term follow-up.\nIndustry Prospects in Favor of PRCT\nPer a report by Grand View Research, the global surgical robotics market was estimated at $3.92 billion in 2023 and is expected to witness a CAGR of 9.5% from 2024 to 2030.\nWith the growing need for minimally invasive therapies, particularly in cancer care, PROCEPT BioRobotics stands to benefit from expanding its Aquablation technology into this new area. If successful, the company could tap into a highly lucrative segment of the healthcare market, further boosting its revenues and overall growth.\nNotable Developments for PRCT\nIn August, PRCT announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. The HYDROS Robotic System represents the next evolution in the delivery of Aquablation therapy, combining cutting-edge technology with user-friendly features designed to deliver better clinical outcomes for patients and healthcare providers.\nIn June, the company announced that the American Medical Association had established a new Current Procedural Terminology Category I code for transurethral waterjet resection of prostate tissue (Aquablation therapy) to treat BPH.\nPRCT’s Zacks Rank & Other Stocks to Consider\nPRCT carries a Zacks Rank #2 (Buy) at present.\nSome other top-ranked stocks in the broader medical space are Inspire Medical INSP, TransMedics Group TMDX and Boston Scientific BSX. While Intuitive Surgical and TransMedics currently sport a Zacks Rank #1 (Strong Buy), Quest Diagnostics carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.\nInspire Medical’s shares have surged 60.5% in the past year. Estimates for the company’s earnings have moved 5.1% north to $1.65 per share for 2024 in the past 30 days.\nISRG’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 436.2%. In the last reported quarter, it posted an earnings surprise of 328.6%.\nEstimates for TransMedics’ 2024 EPS have moved up 125% to 27 cents in the past 30 days. Shares of the company have soared 135.2% in the past year compared with the industry’s 14.9% growth.\nTMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.\nEstimates for Boston Scientific’s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 55.5% compared with the industry’s 17.9% growth.\nIn the last reported quarter, BSX delivered an earnings surprise of 6.90%. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nInspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report\nTransMedics Group, Inc. (TMDX) : Free Stock Analysis Report\nPROCEPT BioRobotics Corporation (PRCT) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474402814"}